Crossmark

A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors

Crossref DOI link: https://doi.org/10.1007/s10637-025-01589-6

Published Online: 2025-11-10

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chan, Hoi Wai

Tse, Chris Chun Long

Li, Yu-Chung

Leung, Roland

Kwok, Gin Wai

Wong, Jeffrey Sum Lung

Li, Karen Hoi-Lam

Tsang, Josephine Wing Yan

Li, Cho Wing

Lo, Jenny Wai Yan

Tang, Vikki

Hui, Rina

Yau, Thomas

Ho, James Chung Man

Chiu, Joanne Wing Yan
Funding

Funding for this research was provided by:

Hong Kong Research Grants Council (17126819)
License Information

Text and Data Mining valid from 2025-11-10

Version of Record valid from 2025-11-10
More Information

Article History

Received: 25 August 2025

Accepted: 3 October 2025

First Online: 10 November 2025

Declarations

:

: This trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The protocol was approved by the institutional review board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (ref. UW 20–205). The study design and conduct complied with all relevant local regulations regarding the use of human study participants.

: Informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below